Adjunct antibiotic combination therapy for steroid-refractory or -dependent ulcerative colitis: an open-label
1Division of Research Planning and Development, Nihon University School of Medicine, Tokyo, Japan.
Alimentary Pharmacology & Therapeutics
|March 18, 2014
Summary
Antibiotic combination therapy effectively treated active ulcerative colitis (UC) in patients dependent on or refractory to steroids. This 2-week treatment demonstrated significant clinical response and remission rates, offering a safe therapeutic option.
Area of Science:
- Gastroenterology
- Microbiology
- Clinical Therapeutics
Background:
- Ulcerative colitis (UC) management often involves steroids, but some patients become dependent or refractory.
- Previous studies indicated antibiotic combination therapy's efficacy in inducing and maintaining UC remission.
Observation:
- A multicentre, open-label trial assessed antibiotic combination therapy in active UC patients with steroid dependency or refractoriness.
- Patients received amoxicillin, tetracycline, and metronidazole for two weeks alongside conventional treatment.
Findings:
- Clinical response was observed in 63.3% of steroid-refractory and 73.4% of steroid-dependent patients within two weeks.
- At 3 and 12 months, clinical remission rates were 60-66.6% for steroid-refractory and 56.3-51.6% for steroid-dependent patients.
- Over 60% of steroid-dependent patients successfully discontinued steroid therapy while maintaining remission.
Implications:
- Two-week antibiotic combination therapy shows promise as an effective and safe treatment for steroid-resistant or steroid-dependent active UC.
- This therapeutic approach may reduce reliance on steroids and improve long-term outcomes in specific UC populations.
Related Concept Videos
01:29Drugs for Treatment of Ulcerative Colitis in IBD
705
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
705
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
755
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
755
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
692
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
692
01:24Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
2.3K
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
2.3K
01:20Inflammatory Bowel Disease II: Ulcerative Colitis
34
Ulcerative colitis is a chronic inflammatory disorder of the colon characterized by continuous mucosal inflammation that typically begins in the rectum and extends proximally in a uniform pattern. Its pathogenesis involves a complex interplay of genetic predisposition, immune dysregulation, and environmental influences. These factors converge to impair the colon’s epithelial defenses and promote an exaggerated inflammatory response against luminal contents.Breakdown of the Mucosal...
34
01:29Inflammatory Bowel Disease IV: Pharmacological Management
1.1K
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
1.1K